30 closest matches · ranked by relevance
Liver Transplant · Liver Transplantation
Primary: Proportion of Participants Successfully Withdrawn From Immunosuppression — 0.60 Proportion of participants
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Hepatitis C · Hepatitis C, Chronic · Nonimmune Nonviral Causes of Liver Failure
Primary: Number of Participants With Clinical Complications Usually Attributed to Immunosuppression — 12; 4 participants
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Liver Failure
Primary: The Incidence of Acute Kidney Injury (AKI) as Assessed by Change in Serum Creatinine From Baseline to 30 Days Post-transplant — .01; .06 mg/dL
Liver Transplant Recipient · Living Donor (of the Respective Liver Transplant Recipient)
Primary: Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs) Deemed Attributable to darTreg Infusion — 0 Participants
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Lung Transplant
Primary: Percentage of Patients Remaining on Envarsus XR at 1 Year — 40 Participants
Medication Adherence · Liver Transplantation · Kidney Transplantation
Primary: Medication Adherence Via Medication Level Variability Index (MLVI) — 23; 24; 10; 8 Participants
End Stage Renal Failure With Renal Transplant
Primary: Change in T Cell & B Cell Generation — 1.05; 0.93; 0.8; 1.12 Mean % of Treg cells in peripheral blood
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants
Influenza, Human · Transplantation Infection
Primary: Number of Patients With Local Site Reactions — 2; 2 Participants
Immunosuppression
Primary: Mean International Society for Heart and Lung Transplantation Biopsy Score Over the First 6 Months Post-transplantation — 0.7; 0.65 units on a scale
Kidney Transplantation
Primary: Tacrolimus Bioavailability (F) — 0.224; 0.681 ratio of oral to IV — p=0.006
Liver Transplantation
Primary: Amount of Treg Cells Observed in Peripheral Blood in Patients With and Without Rejection — 10; 5 percentage of CD4 positive cell
Asses Immunosuppression Modulation on Renal Recovery Post LT
Primary: Participants Who Have Recovered Renal Function — 28; 20; 11 Participants
Liver Transplantation
Primary: Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant — 1.2; 19.7 Percent change in GFR (mL/min) — p=0.0012
Reperfusion Injury
Primary: Peak Aspartate Aminotransferase Within First 72h Post Transplant — 1262.9; 1451.2 U/L
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (GFR) — 73.46; 71.95 mL/min — p=0.097
Renal Failure Chronic · Hepatitis C
Primary: Number of Participants With Undetectable HCV — 30 Participants
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
End Stage Renal Disease
Primary: Number of Subjects Cured — 62 Participants
End Stage Renal Disease · Hepatitis C
Primary: Viral Response as Assessed by Number of Participants With Undetectable Hepatitis C RNA — 10 Participants
Organ Transplantation
Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants
Kidney Transplant
Primary: Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation — 2 Participants
Liver Transplantation
Primary: Estimated Glomerular Filtration Rate (eGFR) at 12 Months Post-surgery — 72; 87.8; 51.0 mL/min
Lung Diseases
Primary: Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment — 10 Participants
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
Kidney Transplantation
Primary: Post-transplant Biopsy to Identify Rejection Episodes — 2; 3 Episode of rejection
Acute Rejection of Liver Transplant · Effects of Immunosuppressant Therapy
Primary: Proportion of Tolerant Patients Off SRL Therapy With Normal Liver Biochemistry and Graft Histology at 12 Months — 8 Participants